Spruce Biosciences (SPRB) Long-Term Investments (2021 - 2022)
Spruce Biosciences (SPRB) posted quarterly Long-Term Investments of $5.8 million for Q2 2022, down 80.5% year-over-year from $29.8 million in Q2 2021, and down 67.02% quarter-over-quarter from $17.6 million in Q1 2022.
Spruce Biosciences (SPRB) Long-Term Investments (2021 - 2022) Analysis & Trends
Spruce Biosciences (SPRB) has reported Long-Term Investments for 2 consecutive years, with $5.8 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Long-Term Investments fell 80.5% year-over-year to $5.8 million; the TTM figure through Jun 2022 stood at $5.8 million (down 80.5% YoY), while the FY2021 annual figure was $32.5 million, changed N/A from the prior year.
- Long-Term Investments retreated to $5.8 million in Q2 2022 per SPRB's latest filing, from $17.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $39.0 million in Q3 2021 and bottomed at $5.8 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 5.81 Mn |
| Mar 31, 2022 | 17.60 Mn |
| Dec 31, 2021 | 32.46 Mn |
| Sep 30, 2021 | 38.98 Mn |
| Jun 30, 2021 | 29.77 Mn |